Search clinical trials for: lixisenatide AVE0010

Total 111 results

Sanofi

Completed

Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Canada, Brazil, Poland, Romania, Russian Federation, Ukraine
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O1)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

Type 2 Diabetes Mellitus

China, India, Korea, Republic of, Russian Federation
Sanofi

Completed

Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

South Africa, United States, Mexico, United Kingdom
Sanofi
Profil GmbH, Neuss, Germany

Completed

Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2 (RESTORE)

Diabetes Mellitus, Type 2

Germany
Sanofi

Completed

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA)

Acute Coronary Syndrome

Belgium, China, Japan, Denmark, United States, Belarus, Mexico, Philippines, Israel, Austria, Serbia, Estonia, Lithuania, Chile, Colombia, Germany, Latvia, Peru, Ukraine, Egypt, Italy, France, Brazil, India, Guatemala, South Africa, Taiwan, C... and more
Sanofi

Terminated

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Type II Diabetes Mellitus
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) (GETGOAL-MONO)

Diabetes Mellitus, Type 2

Japan
Sanofi

Completed

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) (LixilanOne CAN)

Type 2 Diabetes Mellitus

Canada
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-M)

Diabetes Mellitus, Type 2

United States, Canada, Romania, Russian Federation, Ukraine, Germany, Spain, Philippines, Czech Republic, Mexico, Croatia, Chile, Morocco, South Africa, Australia, Venezuela
Sanofi

Completed

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Mexico, South Africa, United States, Mauritius, Spain, Turkey
Sanofi

Completed

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (GETGOAL-S)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Germany, Netherlands, Turkey, Bulgaria, India, Taiwan, Czech Republic, Tunisia, Japan, Egypt, Israel, Korea, Republic of, Thailand
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, India, Belgium, Mexico, Tunisia, Japan, Israel, Korea, Republic of
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (GETGOAL-L)

Diabetes Mellitus, Type 2

United States, France, Canada, Brazil, Russian Federation, Germany, Italy, Turkey, India, Mexico, Egypt, United Kingdom, Korea, Republic of, Chile, Puerto Rico
Sanofi

Completed

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan (LixiRam)

Diabetes Mellitus, Type 2

Israel, India, Kuwait, Turkey
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-F1)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Romania, Ukraine, Germany, Italy, Estonia, Malaysia, Philippines, Mexico, Lithuania, Colombia, Slovakia, Chile
Sanofi

Completed

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (GetGoal-M-Asia)

Type 2 Diabetes Mellitus

China, Hong Kong, Malaysia, Thailand
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (GetGoal-O)

Type 2 Diabetes

United States, Australia, Bulgaria, Canada, Denmark, Germany, Norway, Peru, Poland, South Africa, Spain, Sweden, United Kingdom
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (LixiLan-O)

Type 2 Diabetes

Australia, Denmark, South Africa, Spain, Belgium, Russian Federation, Canada, Estonia, Hungary, Latvia, Mexico, United States, Chile, Czech Republic, France, Germany, Italy, Lithuania, Poland, Romania, Sweden, Ukraine, United Kingdom
Sanofi

Completed

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (Soli-CGM)

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (GETGOAL-P)

Diabetes Mellitus Type 2

United States, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) (GETGOAL-L-ASIA)

Diabetes Mellitus, Type 2

Philippines, Taiwan, Japan, Korea, Republic of
Sanofi

Completed

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (Lixilan-O-AP)

Type 2 Diabetes Mellitus

China, Korea, Republic of, Malaysia, Taiwan
Sanofi

Completed

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Type 2 Diabetes Mellitus

Spain, United States, Canada, Czech Republic, France, Germany, Poland, Romania, Russian Federation, Ukraine
Sanofi

Completed

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin (Lixilan-L-CN)

Type 2 Diabetes Mellitus

China
Sanofi

Terminated

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents (LixiLan-D)

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O2)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs (LIXILAN JP-L)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Type 2 Diabetes Mellitus

India
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-X)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Russian Federation, Germany, Italy, Netherlands, Spain, Sweden, Argentina, Denmark, Finland, Hungary, Norway, Colombia, Austria, Greece, Puerto Rico
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Sanofi

Completed

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Type 2 Diabetes Mellitus

Brazil, Peru, United States, Australia, Canada, Chile, Germany, Guatemala, Mexico, Poland, Romania, Russian Federation, Ukraine
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States, Chile, Czech Republic, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
Sanofi

Completed

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-L)

Type 2 Diabetes

United States, Australia, Canada, Chile, Czech Republic, Denmark, Estonia, Hungary, Lithuania, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine
Sanofi

Completed

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Type 2 Diabetes Mellitus

Japan
University Hospital, Gentofte, Copenhagen
MCM Vaccines B.V.

Completed

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects (Px-Lixi)

Diabetes After Total Pancreatectomy
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes (LIRA-LIXI™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, France, Finland, Germany, Hungary, Latvia, Lithuania, Italy, Czech Republic
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2)

Type 2 Diabetes

United States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (LixiLan-G)

Type 2 Diabetes Mellitus

Estonia, Italy, Israel, United States, Canada, Germany, Romania, Slovakia, Spain
University of Tartu
Tartu University Hospital

Recruiting

The Effect of Lixisenatide on the Effect of Pituitary Hormones

Healthy | Type 1 Diabetes

Estonia
Population Health Research Institute
Sanofi

Completed

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi (REMIT-iGL)

Type 2 Diabetes Mellitus

Canada
Lund University

Completed

Study on Lixisenatide and Counterregulation to Hypoglycemia

Type 2 Diabetes

Sweden
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
Sanofi

Completed

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Type 2 Diabetes Mellitus

China

3

Subscribe